Proactive Investors - Run By Investors For Investors

ANGLE shares rise 11% after its tumour cell detection device is deployed in cancer advance

The Parsortix system was used to capture and assess circulating tumour cells (CTCs) – the tiny tell-tale signs of cancer
ANGLE shares rise 11% after its tumour cell detection device is deployed in cancer advance
The latest work by the team at the MD Anderson Cancer Center was published in the prestigious academic journal Nature

Shares in ANGLE PLC (LON:AGL) (OTCQX:ANPCY) rose 11% after it said its liquid biopsy system was used to assess the metastatic potential of breast cancer.

Metastasis is the process by which cancer spreads from its primary location.

READ: ANGLE ground-breaking liquid biopsy to be used in lung cancer study

Parsortix was used to capture and assess circulating tumour cells (CTCs) – the tiny tell-tale signs of cancer. Researchers at the University of Texas MD Anderson Cancer Center then used a new technique called transmembrane receptor dynamics to distinguish between invasive cancer cells and less-invasive cells.

Being able to make such a distinction would allow doctors to offer more personalised treatments to patients.

The latest work by the team at the MD Anderson Cancer Center was published in the prestigious academic journal Nature.

"This study is the 19th peer-reviewed publication by a leading independent cancer centre demonstrating successful use of ANGLE's world leading Parsortix CTC system,” said the company’ chief executive, Andrew Newland.

“We are pleased to see new applications of the system being developed by independent users of Parsortix, all of which add to the body of evidence and generate new commercial opportunities."

Broker finnCap said the peer-reviewed article provided “further independent endorsement of the utility of Parsortix”.

The shares were trading 7.5p higher at 76p.

---adds broker quote and share pric---

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use